William Comanor, PhD

Professor, Economics, University of California, Santa Barbara

William S. Comanor is Professor of Economics at the University of California, Santa Barbara (UCSB), and also Professor in the Department of Health Policy and Management in the UCLA Fielding School of Public Health. At UCLA, he serves as Director of the UCLA Research Program in Pharmaceutical Economics and Policy and has directed a seminar on pharmaceutical economics for more than 20 years. His doctoral dissertation at Harvard University was entitled: “The Economics of Research and Development in the Pharmaceutical Industry;” and he has continued to study, lecture, publish, and consult on many issues dealing with pharmaceutical economics.

At UCSB, he is the past Director of the MA Program in Economics and regularly teaches a course in Antitrust Economics. He received his Ph.D. in economics from Harvard University and was a post-doctoral fellow at the London School of Economics. Prior to joining the faculty at the University of California, he was on the faculties of both Harvard and Stanford Universities. He has authored and edited 5 books and over 100 professional articles in economics; and was designated a Distinguished Fellow of the Industrial Organization Society in 2003. In addition to his academic positions, Dr. Comanor has served twice with the federal antitrust enforcement agencies in Washington, DC. He served as Special Economic Assistant to the head of the Antitrust Division, U.S. Department of Justice in 1965-66, and also as Chief Economist and Director of the Bureau of Economics, U.S. Federal Trade Commission from 1978 to 1980.

Z. John Lu, PhD

Assistant Professor of Economics at the MVS School of Business and Economics, California State University, Channel Islands

Dr. Z. John Lu is an assistant professor of economics at the MVS School of Business and Economics, California State University, Channel Islands. Prior to this position, Dr. Lu was a health economist in the biopharmaceutical industry for 2 decades, including nearly 17 years at Amgen, where he was a director of global health economics responsible for new drug pricing, reimbursement, and public policy. He is a co-author (with Prof. Stuart Schweitzer of UCLA) of an upcoming new book on pharmaceutical economics titled Pharmaceutical Economics and Policy: Perspectives, Problems, and Promises (3rd edition, Oxford University Press). His research interests extend to economics and policy issues affecting the industry worldwide.
 

This event is free and open to the public, but please register.